Metoprolol

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.

Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Amlodipine (or S-Amlodipine, the pure chirally active enantiomer with lower incidence of ankle edema) is a third-generation dihydropyridine calcium channel blocker on the WHO Model List of Essential Medicines. It inhibits transmembrane influx of extracellular calcium ions into vascular smooth muscle and cardiac muscle through L-type channels, resulting in potent peripheral arterial and coronary vasodilation with an exceptionally long half-life (30-50 hours). Indicated for essential hypertension, chronic stable angina pectoris, and vasospastic (Prinzmetal's) angina.

Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.